Botulinum toxin type A (Incobotulinum toxin A) in spastic forms of cerebral palsy: a retrospective analysis of clinical experience

Kurenkov A.L.; Kuzenkova L.M.; Bursagova B.I.; Klochkova O.A.; Chernikov V.V.; Kuznetsova M.A.; Ashrafova U.S.; Kuprianova O.S.

doi:https://doi.org/10.17116/jnevro202012007168

Kurenkov A.L.

National Medical Research Center for Children’s Health

SPIN RSCI: 8579-3765
Scopus AuthorID: 6603634903
ORCID: 0000-0002-7269-9100

Kuzenkova L.M.

National Medical Research Center for Children’s Health

Bursagova B.I.

National Medical Research Center for Children’s Health

Klochkova O.A.

National Medical Research Center for Children’s Health

Chernikov V.V.

National Medical Research Center for Children’s Health

Kuznetsova M.A.

National Medical Research Center for Children’s Health

Ashrafova U.S.

National Medical Research Center for Children’s Health

Kuprianova O.S.

National Medical Research Center for Children’s Health

Botulinum toxin type A (Incobotulinum toxin A) in spastic forms of cerebral palsy: a retrospective analysis of clinical experience

Authors:

Kurenkov A.L., Kuzenkova L.M., Bursagova B.I., Klochkova O.A., Chernikov V.V., Kuznetsova M.A., Ashrafova U.S., Kuprianova O.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7): 68‑77

DOI: 10.17116/jnevro202012007168

Read: 2213 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kurenkov AL, Kuzenkova LM, Bursagova BI, et al. . Botulinum toxin type A (Incobotulinum toxin A) in spastic forms of cerebral palsy: a retrospective analysis of clinical experience. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7):68‑77. (In Russ.)
https://doi.org/10.17116/jnevro202012007168

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

A retrospective analysis of the experience of using Incobotulinum toxin A injections for the treatment of spasticity in children with cerebral palsy (CP).

MATERIAL AND METHODS

One hundred and eighty-five children with spastic forms of CP, including 114 boys (61,6%), were studied. The average age of the patients was 3,8±2,5 years; the average weight was 14,2±6,9. The patients received injections of Incobotulinum toxin A according to registered indications or recommendations of a consultation of specialists and voluntary informed consent of the patient’s representative. At least 1 point decrease of muscle tone according to the modified Ashworth scale was used as a criterion of the antispastic effect of Incobotulinum toxin A.

RESULTS

The total dose of Incobotulinum toxin A for the whole group of patients with CP was 154,5±67,7 U and 11,6±4,7 U per kg/body weight. The gracilis muscle (65,4% of cases, 95%CI 58,1—72,2) and the gastrocnemius muscle (49,4% of cases, 95%CI 41,8—56,6) were the most frequently injected targets in the lower extremities, and the pronator teres muscle (58,9% of cases, 95%CI 51,5—66,1) — in the upper extremities. Adverse events were observed in 13 patients (7,0%). They were mild in 9 patients and moderate in 4 patients.

CONCLUSION

Our data confirmed the effectiveness and safety of Incobotulinum toxin A injections in spastic CP. The calculated average doses of Incobotulinum toxin A for target muscles and the frequency of different spasticity patterns could serve as a reference for the botulinum therapy planning.

Keywords:

cerebral palsy

botulinum toxin type A

Incobotulinum toxin A

modified Ashworth scale

spasticity

Authors:

Kurenkov A.L.

National Medical Research Center for Children’s Health

SPIN RSCI: 8579-3765
Scopus AuthorID: 6603634903
ORCID: 0000-0002-7269-9100

Kuzenkova L.M.

National Medical Research Center for Children’s Health

Bursagova B.I.

National Medical Research Center for Children’s Health

Klochkova O.A.

National Medical Research Center for Children’s Health

Chernikov V.V.

National Medical Research Center for Children’s Health

Kuznetsova M.A.

National Medical Research Center for Children’s Health

Ashrafova U.S.

National Medical Research Center for Children’s Health

Kuprianova O.S.

National Medical Research Center for Children’s Health

Received:

18.05.2020

Accepted:

20.05.2020

Close metadata

References:

Koman LA, Mooney JF 3rd, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-a toxin: Preliminary investigation. J. Pediatr. Orthop. 1993;13:489-495.
Strobl W, Theologis T, Brunner R, Kocer S, Viehweger E, Pascual-Pascual I, Placzek R. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins (Basel). 2015;7(5):1629-1648. https://doi.org/10.3390/toxins7051629
Multani I, Manji J, Hastings-Ison T, Khot A, Graham K. Botulinum toxin in the management of children with cerebral palsy. Paediatr Drugs. 2019;21(4):261-281. https://doi.org/10.1007/s40272-019-00344-8
Koman LA, Mooney JF 3rd, Smith BP, Goodman A, Mulvaney T. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J. Pediatr. Orthop. 1994;14(3):299-303.
Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ. Double-blind study of botulinum toxin A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture. 1999;10(1):1-9.
Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, Root L, Ferrari E, Garcia de Yebenes Prous J, Smith BP, Turkel C, Walcott JM, Molloy PT. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics. 2001;108(5):1062-1071.
Baker R, Jasinski M, Maciag-Tymecka I, Michalowska-Mrozek J, Bonikowski M, Carr L, MacLean J, Lin JP, Lynch B, Theologis T, Wendorff J, Eunson P, Cosgrove A. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev. Med. Child Neurol. 2002;44(10):666-675.
Polak F, Morton R, Ward C, Wallace WA, Doderlein L, Siebel A. Double-blind comparison of two doses of botulinum toxin A injected into calf muscle in children with hemiplegic cerebral palsy. Dev Med Child Neurol. 2002;44:551-555.
Graham HK, Aoki KR, Autti-Rämö I, Boyd RN, Delgado MR, Gaebler-Spira DJ, Gormley ME, Guyer BM, Heinen F, Holton AF, Matthews D, Molenaers G, Motta F, García Ruiz PJ, Wissel J. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11(1):67-79. Review.
Koman LA, Paterson Smith B, Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr. Drugs. 2003;5(1):11-23. Review.
Mall V, Heinen F, Siebel A, Bertram C, Hafkemeyer U, Wissel J, Berweck S, Haverkamp F, Nass G, Döderlein L, Breitbach-Faller N, Schulte-Mattler W, Korinthenberg R. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev. Med. Child Neurol. 2006;48(1):10-13. https://doi.org/10.1017/S0012162206000041
Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, Andersen GL, Aydin R, Becher JG, Bernert G, Caballero IM, Carr L, Valayer EC, Desiato MT, Fairhurst C, Filipetti P, Hassink RI, Hustedt U, Jozwiak M, Kocer SI, Kolanowski E, Krägeloh-Mann I, Kutlay S, Mäenpää H, Mall V, McArthur P, Morel E, Papavassiliou A, Pascual-Pascual I, Pedersen SA, Plasschaert FS, van der Ploeg I, Remy-Neris O, Renders A, Di Rosa G, Steinlin M, Tedroff K, Valls JV, Viehweger E, Molenaers G. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur. J. Paediatr. Neurol. 2010;14:45-66. https://doi.org/10.1016/j.ejpn.2009.09.005
Love SC, Novak I, Kentish M, Desloovere K, Heinen F, Molenaers G, O’Flaherty S, Graham HK; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur. J. Neurol. 2010;17 Suppl 2:9-37. https://doi.org/10.1111/j.1468-1331.2010.03126.x
Fehlings D, Novak I, Berweck S, Hoare B, Stott NS, Russo RN. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. European Journal of Neurology. 2010;17(Suppl. 2):38-56. https://doi.org/10.1111/j.1468-1331.2010.03127.x
Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, Morrison LA, Shrader MW, Tilton A, Vargus-Adams J. Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336-343. https://doi.org/10.1212/WNL.0b013e3181cbcd2f
Delgado MR, Bonikowski M, Carranza J, Dabrowski E, Matthews D, Russman B, Tilton A, Velez JC, Grandoulier AS, Picaut P. Safety and efficacy of repeat open-label AbobotulinumtoxinA treatment in pediatric cerebral palsy. J. Child Neurol. 2017;32(13):1058-1064. https://doi.org/10.1177/0883073817729918
Tilton A, Russman B, Aydin R, Dincer U, Escobar RG, Kutlay S, Lipczyk Z, Velez JC, Grandoulier AS, Tse A, Picaut P, Delgado MR. AbobotulinumtoxinA (Dysport®) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy. J. Child Neurol. 2017;32(5):482-487. https://doi.org/10.1177/0883073816686910
Novak I, Morgan C, Fahey M, Finch-Edmondson M, Galea C, Hines A, Langdon K, Namara MM, Paton MC, Popat H, Shore B, Khamis A, Stanton E, Finemore OP, Tricks A, Te Velde A, Dark L, Morton N, Badawi N. State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. Curr Neurol Neurosci Rep. 2020;20(2):3. https://doi.org/10.1007/s11910-020-1022-z
Leon-Valenzuela A, Sanchez Palacios J, del Pino Algarrada R. Clinical practice with incobotulinumtoxina (Xeomin) in the treatment of spasticity in children with cerebral palsy. Toxicon. 2016;123:S53.
Hijazi S, Arcas M. Effectiveness and safety assessment of incobotulinumtoxina (Xeomin) injections in the lower-limb muscles of young, low-weight children with cerebral palsy. Toxicon. 2016;123:S39.
NeuroKids: child neurology workbook (Ed. Prof. F. Heinen). Kohlhammer, 2017.
Heinen F, Kanovský P, Schroeder SA, Berweck S, Chambers HG, Dabrowski E, Geister TL, Dersch H, Martinez-Torres FJ, Lehn A, Pulte I, Gaebler-Spira D. Efficacy and safety of IncobotulinumtoxinA for lower-limb spasticity in children and adolescents with cerebral palsy. Toxicon. 2018;156:S44.
Kanovský P, Heinen F, Schroeder SA, Berweck S, Chambers HG, Dabrowski E, Geister TL, Dersch H, Martinez-Torres FJ, Lehn A, Pulte I, Martinez-Torres FJ, Gaebler-Spira D. Long-term safety and efficacy of IncobotulinumtoxinA for lower- or combined upper- and lower-limb spasticity in children and adolescents with cerebral palsy. Toxicon. 2018;156:S56.
Thomason P, Rodda J, Willoughby K, Graham K. Orthopaedic assessment. In book: Cerebral palsy: science and clinical practice (Eds. B. Dan, M. Mayston, N. Paneth, L. Rosenbloom). London: Mac Keith Press, 2014;287-311.
Franzen M, Hägglund G, Alriksson-Schmidt A. Treatment with botulinum toxin A in a total population of children with cerebral palsy — a retrospective cohort registry study. BMC Musculoskelet. Disord. 2017;18(1):520. https://doi.org/10.1186/s12891-017-1880-y
Hägglund G, Wagner P. Development of spasticity with age in a total population of children with cerebral palsy. BMC Musculoskelet Disord. 2008;9:150. https://doi.org/10.1186/1471-2474-9-150
Eliasson AC, Burtner P. Improving Hand Function in Children with Cerebral Palsy. London: Mac Keith Press, 2008.
Klochkova OA, Kurenkov AL, Namazova-Baranova LS, Mamedyarov AM. Spasticity patterns of hand muscles and botulinum toxin therapy application in patients with cerebral palsy with upper limb involvment. Pediatricheskaya farmakologiya. 2013;10(5):31-39. (In Russ.).
Carraro E, Trevisi E, Martinuzzi A. Safety profile of incobotulinum toxin A [Xeomin®] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial. Eur J Paediatr Neurol. 2016;20(4):532-537. https://doi.org/10.1016/j.ejpn.2016.04.008
Kurenkov AL, Klochkova OA, Bursagova BI, Karimova KM, Kuzenkova LM, Mamedyarov AM, Namazova-Baranova LS, Agranovich OV, Agranovich AO, Soboleva OA, Khapaeva MM, Batysheva TT, Sarzhina MN. Efficacy and safety of botulinum toxin type A (IncobotulinumtoxinA) in the treatment of patients with cerebral palsy. Zh Nevrol Psikhiatr Im SS Korsakova. 2017;117(11):44-51. (In Russ.). https://doi.org/10.17116/jnevro201711711137-44